TOP TEN perturbations for 1553081_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553081_at
Selected probe(set): 1553081_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553081_at (1553081_at) across 6672 perturbations tested by GENEVESTIGATOR:

keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):-4.483183
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (KLF4 siRNA)
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

skin transplantation study 1 (7d) / split-thickness skin grafting study 1

Relative Expression (log2-ratio):4.163826
Number of Samples:5 / 6
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.

engineered skin substitute study 1 (late) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):3.6595917
Number of Samples:3 / 3
Experimental engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

split-thickness skin grafting study 1 / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-3.5606337
Number of Samples:6 / 8
Experimental split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-3.299529
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):2.9241333
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

skin transplantation study 1 (7d) / skin transplantation study 1 (3d)

Relative Expression (log2-ratio):2.7915316
Number of Samples:5 / 6
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control skin transplantation study 1 (3d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery.

gefitinib study 2 / wild type A431 cell sample

Relative Expression (log2-ratio):-2.716137
Number of Samples:3 / 3
Experimental gefitinib study 2
Gefitinib-resistant A431 (A431 GR) cells generated by growing parental cells in the presence of increasing concentrations of gefitinib up to 3 μM. Cells were selected and maintained in gefitinib (3μM). ATC code:
Control wild type A431 cell sample
A431 wild type cells.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; placebo; 15d)

Relative Expression (log2-ratio):-2.6783543
Number of Samples:8 / 5
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 15d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo.

psoriasis study 5 (NCT00867100; lesional; baseline) / psoriasis study 5 (NCT00867100; non-lesional; baseline)

Relative Expression (log2-ratio):2.6098795
Number of Samples:24 / 24
Experimental psoriasis study 5 (NCT00867100; lesional; baseline)
Lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from lesional skin at baseline.
Control psoriasis study 5 (NCT00867100; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from uninvolved, non-lesional skin at baseline.